SNTI icon

Senti Biosciences

4.06 USD
+0.09
2.27%
Updated Apr 22, 2:31 PM EDT
1 day
2.27%
5 days
20.12%
1 month
9.14%
3 months
-11.16%
6 months
78.07%
Year to date
6.56%
1 year
44.48%
5 years
-95.93%
10 years
-95.93%
 

About: Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Employees: 48

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

34% more capital invested

Capital invested by funds: $2.41M [Q3] → $3.23M (+$824K) [Q4]

14% more funds holding

Funds holding: 14 [Q3] → 16 (+2) [Q4]

3.21% less ownership

Funds ownership: 23.27% [Q3] → 20.06% (-3.21%) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

Research analyst outlook

We haven’t received any recent analyst ratings for SNTI.

Financial journalist opinion

Based on 5 articles about SNTI published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
Senti Bio Participates in a Virtual Investor KOL Connect Segment
Moderated discussion with Stephen Strickland, MD, MSCI, internationally respected leukemia researcher, Director of Leukemia Research for Sarah Cannon Research Institute and Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio
Senti Bio Participates in a Virtual Investor KOL Connect Segment
Neutral
GlobeNewsWire
6 days ago
Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment
Live moderated webcast with members of the Senti Bio management team on Wednesday, April 23rd at 4:00 PM ET Live moderated webcast with members of the Senti Bio management team on Wednesday, April 23rd at 4:00 PM ET
Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment
Neutral
GlobeNewsWire
1 week ago
Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.
Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from “bench to bedside” and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the appointment of James B.
Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.
Neutral
GlobeNewsWire
2 weeks ago
Senti Bio Joins Webull Corporate Connect Service Platform
Company advancing off-the-shelf CAR-NK cell therapy programs for oncology indications with lead candidate, SENTI-202, in clinical development for the treatment of acute myeloid leukemia (AML)
Senti Bio Joins Webull Corporate Connect Service Platform
Neutral
GlobeNewsWire
2 weeks ago
Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
SOUTH SAN FRANCISCO, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that three abstracts have been selected for an oral minisymposium and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL.
Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
Neutral
GlobeNewsWire
1 month ago
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission –        – Strengthened balance sheet with gross proceeds of approximately $47.6 million from private investment in public equity (PIPE) financing – SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2024 and provided a summary of recent pipeline and corporate highlights.
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
Neutral
GlobeNewsWire
1 month ago
Senti Bio Appoints Feng Hsiung to Board of Directors
– Company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) – – Company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) –
Senti Bio Appoints Feng Hsiung to Board of Directors
Neutral
GlobeNewsWire
1 month ago
Senti Bio Strengthens Leadership Team with Strategic Hires
– Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP Technical Operations – SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced an expansion of its senior leadership team with the addition of Jay Cross as Chief Financial Officer and Faraz Siddiqui as Senior Vice President of Technical Operations.
Senti Bio Strengthens Leadership Team with Strategic Hires
Neutral
Accesswire
2 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Senti Biosciences Inc.
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Senti Biosciences Inc.
Neutral
Accesswire
2 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc
Charts implemented using Lightweight Charts™